Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

被引：0
|
作者：
A F List
J M Bennett
M A Sekeres
B Skikne
T Fu
J M Shammo
S D Nimer
R D Knight
A Giagounidis
机构：
来源：
Leukemia | 2015年 / 29卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Correction to: Leukemia (2014) 28, 1033–1040; doi:10.1038/leu.2013.305 Since the publication of this article it has been noted that there was an omission in the listing of conflict of interest. JM Bennett was listed as having no conflict of interest; however, the authors would like to correct this to read:
引用
收藏
页码：2452 / 2452
相关论文
共 50 条
  • [21] Patients with Del(5q) MDS Who Fail to Achieve Erythroid or Cytogenetic Remission After Treatment with Lenalidomide Have An Increased Risk for Clonal Evolution and AML Progression.
    Gohring, Gudrun
    Giagounidis, Aristoteles
    Buesche, Guntram
    Kreipe, Hans
    Zimmermann, Martin
    Hellstrom-Lindberg, Eva
    Aul, Carlo
    Schlegelberger, Brigitte
    BLOOD, 2009, 114 (22) : 1469 - 1469
  • [22] Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression
    Goehring, Gudrun
    Giagounidis, Aristoteles
    Buesche, Guntram
    Kreipe, Hans Heinrich
    Zimmermann, Martin
    Hellstroem-Lindberg, Eva
    Aul, Carlo
    Schlegelberger, Brigitte
    ANNALS OF HEMATOLOGY, 2010, 89 (04) : 365 - 374
  • [23] Disease progression in del(5q) MDS patients treated with lenalidomide: analysis of risk factors and long-term outcome in 44 patients
    Giagounidis, A. A. N.
    Haase, S.
    Lohrbacher, V.
    Heinsch, M.
    Schuran, B.
    Aul, C.
    LEUKEMIA RESEARCH, 2007, 31 : S120 - S121
  • [24] Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
    Valeria Santini
    Pierre Fenaux
    Aristoteles Giagounidis
    Uwe Platzbecker
    Alan F. List
    Torsten Haferlach
    Jim Zhong
    Chengqing Wu
    Konstantinos Mavrommatis
    C. L. Beach
    Kyle J. MacBeth
    Antonio Almeida
    Leukemia, 2021, 35 : 897 - 900
  • [25] Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
    Santini, Valeria
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Platzbecker, Uwe
    List, Alan F.
    Haferlach, Torsten
    Zhong, Jim
    Wu, Chengqing
    Mavrommatis, Konstantinos
    Beach, C. L.
    MacBeth, Kyle J.
    Almeida, Antonio
    LEUKEMIA, 2021, 35 (03) : 897 - 900
  • [26] Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)
    Almeida, Antonio
    Fenaux, Pierre
    List, Alan F.
    Raza, Azra
    Platzbecker, Uwe
    Santini, Valeria
    LEUKEMIA RESEARCH, 2017, 52 : 50 - 57
  • [27] Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
    Komrokji, R. S.
    List, A. F.
    ANNALS OF ONCOLOGY, 2016, 27 (01) : 62 - 68
  • [28] p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study
    Saft, Leonie
    Li, Jack Shiansong
    Greenberg, Peter L.
    Sekeres, Mikkael A.
    Sanz, Guillermo F.
    Dreyfus, Francois
    Fenaux, Pierre
    Swern, Arlene S.
    Sugrue, Mary M.
    Hellstrom-Lindberg, Eva
    BLOOD, 2014, 124 (21)
  • [29] Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial
    Almeida, Antonio
    Fenaux, Pierre
    Garcia-Manero, Guillermo
    Goldberg, Stuart L.
    Groepper, Stefanie
    Jonasova, Anna
    Vey, Norbert
    Castaneda, Carmen
    Zhong, Jianhua
    Beach, C. L.
    Santini, Valeria
    LEUKEMIA & LYMPHOMA, 2018, 59 (09) : 2135 - 2143
  • [30] Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program.
    Le Bras, Fabien
    Sebert, Marie
    Kelaidi, Charikleia
    Lamy, Thierry
    Dreyfus, Francois
    Delaunay, Jacques
    Banos, Anne
    Blanc, Michel
    Vey, Norbert
    Gardembas, Martine
    Visanica, Sorin
    Bauduer, Frederic
    Turlure, Pascal
    Dahoun, Mehdi
    Beyne-Rauzy, Odile
    Guerci, Agnes
    Delmer, Alain
    de Botton, Stephane
    Berthou, Christian
    Besson, Caroline
    Rea, Delphine
    Lefrere, Francois
    Wattel, Eric
    Rousselot, Philippe
    Fenaux, Pierre
    Ades, Lionel
    BLOOD, 2009, 114 (22) : 1080 - 1081
12345